- Home
- IPHA vs DOUG Comparison
IPHA vs DOUG Comparison
Compare IPHA & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- DOUG
- Stock Information
- Founded
- IPHA 1999
- DOUG 1911
- Country
- IPHA France
- DOUG United States
- Employees
- IPHA N/A
- DOUG N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- DOUG Building operators
- Sector
- IPHA Health Care
- DOUG Real Estate
- Exchange
- IPHA Nasdaq
- DOUG Nasdaq
- Market Cap
- IPHA 187.0M
- DOUG 166.2M
- IPO Year
- IPHA 2019
- DOUG N/A
- Fundamental
- Price
- IPHA $2.33
- DOUG $1.67
- Analyst Decision
- IPHA Strong Buy
- DOUG
- Analyst Count
- IPHA 1
- DOUG 0
- Target Price
- IPHA $11.50
- DOUG N/A
- AVG Volume (30 Days)
- IPHA 5.6K
- DOUG 780.1K
- Earning Date
- IPHA 09-12-2024
- DOUG 11-05-2024
- Dividend Yield
- IPHA N/A
- DOUG N/A
- EPS Growth
- IPHA N/A
- DOUG N/A
- EPS
- IPHA N/A
- DOUG N/A
- Revenue
- IPHA $68,134,188.00
- DOUG $951,674,000.00
- Revenue This Year
- IPHA N/A
- DOUG $3.85
- Revenue Next Year
- IPHA $105.84
- DOUG $17.40
- P/E Ratio
- IPHA N/A
- DOUG N/A
- Revenue Growth
- IPHA 6.88
- DOUG N/A
- 52 Week Low
- IPHA $1.81
- DOUG $1.00
- 52 Week High
- IPHA $3.15
- DOUG $3.16
- Technical
- Relative Strength Index (RSI)
- IPHA 52.64
- DOUG 44.48
- Support Level
- IPHA $2.14
- DOUG $1.42
- Resistance Level
- IPHA $2.35
- DOUG $1.91
- Average True Range (ATR)
- IPHA 0.15
- DOUG 0.17
- MACD
- IPHA 0.00
- DOUG -0.05
- Stochastic Oscillator
- IPHA 58.82
- DOUG 30.82
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.